title: Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments.
abstract: Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by intensely pruritic, eczematous changes. First-line therapy includes topical corticosteroids during an exacerbation and long-term emollient use, followed by topical calcineurin inhibitors, phototherapy, and systemic therapy in more difficult cases. The need for more effective AD therapies with safer side effect profiles has pushed researchers to devise new therapies and to recycle traditional treatments for use in a novel manner. Innovative therapies include barrier therapy, novel antistaphylococcal treatments, new immunomodulatory agents, unconventional antipruritic agents, exclusionary diets, and probiotics. Advancements in these options have paved the way for a targeted approach to AD therapy. We will review the latest clinical research exploring these cutting-edge AD treatment modalities and discuss forward-thinking therapy strategies that use conventional AD medications in a novel manner.
authors.affiliation: Dermatology Clinical Research Unit, Department of Dermatology, University of California, Davis, Sacramento, CA 95816, USA.
authors.forename: Elizabeth P
authors.initials: EP
authors.lastname: Chase
authors.forename: April W
authors.initials: AW
authors.lastname: Armstrong
mesh_terms: D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000178:diet therapy / Q000628:therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D004643:Emollients / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D010789:Phototherapy / Q000379:methods; D019936:Probiotics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004643:Emollients; D005938:Glucocorticoids; D007155:Immunologic Factors